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Synthetic cannabinoids are functionally similar to delta9-tetrahydrocannabinol (THC), the
psychoactive principle of cannabis, and bind to the same cannabinoid receptors in the brain
and peripheral organs. From 2008, synthetic cannabinoids were detected in herbal smok-
ing mixtures sold on websites and in “head shops” under the brand name of Spice Gold,
Yucatan Fire, Aroma, and others. Although these products (also known as “Spice drugs” or
“legal highs”) do not contain tobacco or cannabis, when smoked they produce effects simi-
lar toTHC. Intoxication, withdrawal, psychosis, and death have been recently reported after
consumption, posing difﬁcult social, political, and health challenges. More than 140 different
Spice products have been identiﬁed to date.The ability to induce strong cannabis-like psy-
choactive effects, along with the fact that they are readily available on the Internet, still legal
in many countries, marketed as natural safe substances, and undetectable by conventional
drug screening tests, has rendered these drugs very popular and particularly appealing
to young and drug-naïve individuals seeking new experiences. An escalating number of
compounds with cannabinoid receptor activity are currently being found as ingredients of
Spice, of which almost nothing is known in terms of pharmacology, toxicology, and safety.
Since legislation started to control the synthetic cannabinoids identiﬁed in these herbal mix-
tures, many new analogs have appeared on the market. New cannabimimetic compounds
are likely to be synthesized in the near future to replace banned synthetic cannabinoids,
leading to a “dog chasing its tail” situation. Spice smokers are exposed to drugs that are
extremely variable in composition and potency, and are at risk of serious, if not lethal,
outcomes. Social and health professionals should maintain a high degree of alertness for
Spice use and its possible psychiatric effects in vulnerable people.
Keywords: spice, designer drugs, synthetic cannabinoids, addiction, Internet, herbal blends, natural highs,
cannabimimetics
INTRODUCTION
Cannabis is one of the oldest drugs of abuse and its consumption
is still high worldwide. During the past two decades, knowledge
of its pharmacology and the role of the endocannabinoid system
in brain function and physiology has improved greatly (Thakur
et al., 2009; Alger and Kim, 2011). Despite its long history of use
and abuse for both medical and recreational purposes, a new gen-
eration of synthetic cannabinoids has recently emerged on the
market, which are sold on the Internet as herbal mixtures under
the brand names of “Spice,” “Spice Gold,” “Spice Diamond,”“Arc-
tic Spice,” “Silver,” “Aroma,” “K2,” “Genie,” “Scene” or “Dream,”
and advertised as incense products, meditation potpourris, bath
additives, or air fresheners. These products are often referred to
as “herbal highs” or “legal highs” because of their legal status
and purported natural herbal make-up. They are distributed in
the form of dried leaves or resin, although more recently pow-
dery products have also begun to emerge (Kikura-Hanajiri et al.,
2011), and are sold without age restriction in metal-foil sachets,
usually containing 3 g of vegetable matter, to which one or more
of the synthetic cannabinoids have been added. Spice is typically
smoked, using a pipe or by rolling in a cigaret paper, but can also
be ingested as an infusion, or inhaled. These novel and increas-
ingly popular recreational drugs ﬁrst appeared on websites and
in specialized shops (“head shops,” which sell paraphernalia for
cannabis users) around 2004, if not earlier (Dresen et al., 2010),
and are sold as mild hallucinogens with prominent cannabis-like
effects. They soon became popular in Central European coun-
tries, began to catch the attention of a broader public in 2007,
and gained a high degree of popularity in 2008. Consequently,
they have also attracted the attention of the European Moni-
toring Centre for Drugs and Drug Addiction (EMCDDA) early
warning system on new drugs (Early Warning System, 2009;
EMCDDA, 2009). However, it was not before the end of 2008
that two synthetic cannabinoids were identiﬁed for the ﬁrst-time
as the main active (not declared) ingredients of an herbal blend
called “Spice”: the C8 homolog of the non-classical cannabinoid
CP-47,497, CP-47,497-C8, and a cannabimimetic aminoalkylin-
dole called JWH-018 (Auwärter et al., 2009; Uchiyama et al.,
2009a). At the beginning of 2009, legislation in several Euro-
pean countries (Austria, Germany, France, Luxembourg, Poland,
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Lithuania, Sweden, and Estonia) subjected all products contain-
ing these substances to the Narcotics Law, so that Spice and the
other cannabinoid-containing “natural” mixtures were no longer
accessible in head shops and online stores (Figure 1). In the
same year, following advice from the Advisory Council on the
Misuse of Drugs (ACMD, 2009) and the EMCDDA, the Mis-
use of Drugs Act 1971 was amended and classiﬁed synthetic
cannabinoids as controlled substances in the UK (UK Statutory
Instrument, 2009). Far from stopping their sale, prohibition rather
had the effect of facilitating the generation of new follow-up
designer cannabimimetic substances: the aminoalkylindole JWH-
073 (Auwärter et al., 2009; Lindigkeit et al., 2009), the hexyl
homolog JWH-019 (Dresen et al., 2011), and the two more recent
aminoalkylindoles, JWH-250 (Westphal et al., 2010) and JWH-
398 (Hudson et al., 2010). During 2009, the potent synthetic
cannabinoid agonist HU-210 was identiﬁed in Spice products in
the UK (EMCDDA, 2009). Starting from the middle of 2010,
the EMCDDA warned about the presence of JWH-015 in an
herbal mixture called “Topaz” that is sold in Austria, along with
the discovery of a methyl derivative of JWH-073 (1-butyl-3-(1-
(4-methyl)naphthoyl)indole), JWH-122 (1-pentyl-3-(4-methyl-
1-naphthoyl)indole) being a methyl derivative of JWH-018, and
AM-694 (1-(5-ﬂuoropentyl)-3-(2-iodobenzoyl)indole) as the ﬁrst
halogenated aminoalkylindole found in an herbal mixture (Ernst
et al., 2011). On March 2011, the Drug Enforcement Administra-
tion (DEA) issued the ﬁnal order to temporarily ban ﬁve synthetic
cannabinoids, namely JWH-018, JWH-073, JWH-200, CP-47,497,
and CP-47,497-C8. Currently, there are no more doubts that these
Spice-like products are no longer limited to European Coun-
tries but rather have spread worldwide, from Ukraine, to Taiwan,
to the USA (Vardakou et al., 2010), and a growing number of
countries are currently implementing their own law or policy
of controlling at one or more of these synthetic cannabinoids
(Drug Policy Alliance, 2011). In Europe, the emergence of Spice
drugs has became a major alarm for the Europol’s Organised
Crime Threat Assessment (OCTA, 2011), while in the USA start-
ing from February 2011, the Uniform Code of Military Justice
(UCMJ) banned Spice and US Air Force is now screening urine
tests for synthetic cannabinoids (Air Force Times, 2011; UCMJ,
2011).
FIGURE 1 |Timeline of synthetic cannabinoids and Spice products.
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DRUG QUEEN OF THE WEB
The presence of websites dedicated to the use of recreational con-
trolled drugs as well as the use of cyberspace for the assessment
of the drug abuse market are not recent phenomena (Rawaf and
Schifano, 2000; Schifano et al., 2003, 2006). Yet, the role played
by the Internet as one of the major markets for novel designer
drugs is increasingly alarming (Corazza et al., 2011). To date,
new Spice products that purportedly contain synthetic cannabi-
noids appear in the online market on a regular basis and their
popularity has grown rapidly in the past few years (Fabrizio Schi-
fano, personal communication). Tracking the world wide web,
it is clear that the vast majority of legal highs are purchased
online, which partly explains why Spice use is so widespread and
causes social and medical concern (Burley, 2008; Vardakou et al.,
2011). There are an increasing number of websites where users
can order Spice blends or pure JWH compounds without age
restriction or any type of control. Amazingly, with a few clicks
of a mouse, many highly psychoactive substances can be obtained
cheaply and legally (Schmidt et al., 2011). On a growing number
of blogs, users report their own mixtures and testing procedures,
describe subjective side effects, and express their preference for
their favorite smoking blends. That is, in a smoking blend compe-
tition, “Spice Diamond” was elected as the best smoking product
among 41 different mixtures (Vardakou et al., 2010). Looking at
the different Internet fora, it appears that users are perfectly con-
scious of the cannabis-like effects of these herbal blends; they
know that their psychoactive properties are mainly due to syn-
thetic cannabinoids, and more surprisingly, in most cases, they are
aware that these compounds have never been tested for human
consumption.
A dramatic online snapshot of the Spice phenomenon as an
emerging trend has been recently given by an important web map-
ping program, the Psychonaut Web Mapping Project, a European
Commission-funded project involving researchers from seven
European countries (Belgium, Finland, Germany, Italy, Norway,
Spain, and UK), which aims to develop a web scanning system
to identify newly marketed psychoactive compounds, and their
combinations (e.g., ketamine and Spice, cannabis and Spice), on
the basis of the information available on the Internet (Psycho-
naut Web Mapping Research Group, 2010). As a major result of
the Project, a new and updated web-based database is now widely
accessible to implement a regular monitoring of the web for novel
and recreational drugs1.
By monitoring fora, blogs, and chats, as well as e-newsgroups,
chat rooms, mailing lists, e-newsletters, and bulletin boards
in eight languages (Dutch, English, Finnish, German, Italian,
Norwegian, Spanish, and Swedish), Professor Fabrizio Schifano
(the Scientiﬁc Coordinator of the Psychonaut Web Mapping
Project) and collaborators have found that online users mostly
appreciate Spice products for their psychoactive effects, lack of
detection in body ﬂuids, ease of online access, and legal sta-
tus, although some consumers have reported unpleasant side
effects, such as paranoia, cramps, strong headache, mild hallu-
cinations, and vomiting (Schifano et al., 2009). Although the
1http://www.psychonautproject.eu
provenance of these herbal mixture is often not clear, the project
has identiﬁed potential wholesalers and manufacturers of Spice,
including a UK company (Psyche Deli) and a Dutch company
(Zonged.eu/MultiNETional), although some Spice products seem
to be imported from China (Jack, 2009). Notably, not only
Spice mixtures but also related merchandise, such as an infor-
mative CD explaining their psychoactive effects, can be found
on sale on eBay (Aurazendoctor, 2009). It is clear that the Inter-
net offers an overabundance of drug-related data that are con-
stantly one step ahead of those available to clinicians and law
enforcement authorities (Boyer et al., 2001). Likewise, the poor
quality of product information provided to consumers is par-
ticularly worrying, because the majority of the websites have
inconsistent information available to users (Hillebrand et al.,
2010).
WHY CANNABINOID DESIGNER DRUGS ARE SO POPULAR
THEY INDUCE PSYCHOACTIVE EFFECTS
According to discussions on retailers’ websites, Spice smokers ﬁnd
drug effects similar to those of marijuana, leading to the hypoth-
esis that many users smoke it as a legal alternative to cannabis.
Apparently labeled as incense, the herbal constituents listed on the
packaging of Spice have been deliberately contaminated with syn-
thetic cannabinoids (mainly JWH-018) to induce cannabimimetic
effects (Steup, 2009). Thus, while the natural ingredients of these
herbal mixtures seem not to possess psychoactive properties per se,
synthetic cannabinoids are probably mixed into a solvent and then
sprayed on aplant-derived base for delivery, leading to a ﬁnal prod-
uct with potent cannabis-like properties (Vardakou et al., 2010).
Their agonistic activity on the CB1 receptor is responsible for ele-
vating mood and inducing a feeling of well-being. Some Spice
users have reported effects similar to or even stronger than those
obtainedby smoking cannabis, such as physical relaxation, changes
in perception, and mild euphoria. The higher potency of action
of these synthetic cannabinoids might be explained by in vitro
experiments that have suggested that, while THC acts as a partial
agonist on the CB1 receptor, JWH-018 acts as a full and potent
agonist (Atwood et al., 2010). Moreover, compared with THC,
JWH-018 possesses approximately a fourfold higher afﬁnity to
the cannabinoid CB1 receptor and 10-fold higher afﬁnity to CB2
receptor (Aung et al., 2000; Huffman and Padgett, 2005). With
respect to other products containing non-controlled plants and
fungi and marketed as legal highs (e.g., Salvia divinorum or khat),
Spice blends better satisfy users’ expectations, in that their psy-
choactive effects are perceived to be even stronger than cannabis
(Grifﬁths et al., 2010). Regrettably, safety information provided is
sparse and of uncertain utility, with only a few products warnings
about potential adverse effects or drug interactions.
THEY ARE LEGAL
Spices are often referred to as legal highs, in that they are neither
controlled by the 1971 Misuse of Drugs Act, nor licensed for legal
use such as alcohol and nicotine. Both the use and possession of
these drugs have been long ofﬁcially authorized, and their supply
tolerated as long as they are sold for purposes other than human
consumption. The relatively recent identiﬁcation of the ﬁrst
synthetic cannabinoids as not declared ingredients of Spice
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marked a signiﬁcant turning point in this situation. Indeed,
although structurally distinct from THC, synthetic cannabinoids
are part of the well-characterized aminoalkylindole class of lig-
ands that also bind and activate CB1 receptors. Although their
government regulation is still inconsistent or even lacking in many
countries, Spice products are currently controlled in 14 European
nations (Austria, Denmark, Estonia, France, Germany, Ireland,
Italy, Latvia, Lithuania, Luxembourg, Poland, Romania, Sweden,
and UK), where they are classiﬁed as pharmaceuticals or nar-
cotics. Yet, they are still legal and uncontrolled in the remaining
parts of Europe and many other countries, leading to heavy global
marketing.
In the USA, some states (Alabama, Arkansas, Georgia, Kansas,
Kentucky, and Missouri) have taken legislative action against the
distribution and use of Spice, and until recently, only one syn-
thetic cannabinoid, namely HU-210, was considered a Schedule I
substance (unsafe, highly abused, no medical usage). On Novem-
ber 24, 2010, the United States Drug Enforcement Administration
temporarily added to the list the following synthetic cannabinoids:
JWH-018, JWH-073, JWH-200, CP-47,497, and cannabicyclo-
hexanol (US Department of Justice Drug Enforcement Adminis-
trationDrugs andChemicals of Concern, 2010). JWHcompounds
(i.e., JWH-018, JWH-015, and JWH-073) are also currently unreg-
ulated in New Zealand and are easily obtainable in head shops and
from many websites (Every-Palmer, 2011).
However, regulatory mechanisms are weak and difﬁcult to
enforce when controlled products are available on the Internet,
because online retailers can evade easily national jurisdiction and
supply Spice products to other countries but not their own. In
addition, experience has shown that, as legal authorities adopt
control measures, other synthetic cannabinoids are soon added to
existing Spice-like products, suggesting that the producers expect
prohibition and are ready to synthesize an assortment of sub-
stitutes (Lindigkeit et al., 2009). It looks like the producers are
moving onto the next product, always one step ahead of the law
(Dargan et al., 2011). This is not totally unexpected because there
is a high demand for legal highs (United Nations Ofﬁce on Drugs
and Crime, 2011; Zawilska, 2011), implying that it will be satisﬁed
by products containing chemical ingredients that are not yet pro-
hibited. Lack of consistency in the measures adopted to control
the market, ranging from medical legislation to formal drug con-
trol instruments, is another major point of concern in monitoring
and responding to worldwide circulation of Spice (ACMD, 2009;
McLachlan, 2009).
THEY ARE READY AVAILABLE AND HIGHLY ATTRACTIVE
Marketed under the generic brand name of Spice, an increas-
ing number of herbal mixtures are sold mainly on the Internet,
and in some countries, in dedicated shops that offer legal alter-
natives to prohibited drugs. The price is affordable also by young
people, roughly C9–12 per gram: each sachet typically contains
3 g of smoking mixture, sufﬁcient for around eight joints, and
costs C27–36. As reported in a warning editorial by Grifﬁths
et al. (2010), the Spice phenomenon represents a clear example of
how globalization brings major challenges to the control of new
drugs marketing, in that a user living in a country where Spice is
controlled can buy it from a foreign retailer.
It is noteworthy that themulticolored packaging of these herbal
blends is very attractive and highly sophisticated; many of them
have a wide-open-eye imprint and circulate under exotic brand
names, such as “Tropical Synergy” or “Yucatan Fire” (Sobolevsky
et al., 2010). Although the product label often states that the prod-
uct is “not for human consumption” or “for aromatherapy only,”
the composite blend of ingredients listed on the pack suggests the
opposite, suggesting that the purpose of such a statement is to
elude the interest of the medicines and healthcare products regu-
latory agencies. Because of their packaging resembling incense or
tea and their scented smell, Spice products are far less noticeable as
drugs, are not easily identiﬁed by parents or carers, and can com-
fortably be consumed at home. Thus, they are extremely tempting
for young people that are willing to try cannabis but are afraid of
the legal consequences and/or the reputation.
THEY ARE PERCEIVED AS SAFE DRUGS
Commercial advertisements describing Spice as “natural herbs”or
“harmless incense blend” are very colorful and use intuitive (ﬁgu-
rative) language, resulting in greater attractiveness for vulnerable
individuals who might not otherwise smoke cannabis, in particu-
lar adolescents wishing to have a “safe” experience. Lack of safety
information could lead to the incorrect supposition that herbal
mixtures are safe, especially amongst ﬁrst-time users. These herbal
blends typically have a pleasurable smell and taste (i.e., honey or
vanilla), are delivered in attractive packaging, often as pre-rolled
cigarets, and are marketed as “incense cones.” For some people,
undesirable psychoactive effects and public perception of cannabi-
noid use could representmajor limitations in the use of marijuana:
Spice circumvents these limits by appearing as a safer alternative
to cannabis. People that have been warned against using cannabis
for legislative (i.e., after a period in prison or a forensic hospital)
or medical (i.e., predisposition to psychotic illness) reasons might
also ﬁnd Spice a safe (and undetectable) drug to use. Moreover,
Spice products represent a tempting alternative for those who have
experienced adverse effects from smoking marijuana (ACMD,
2009; EMCDDA, 2009). However, all Spice products introduced
into the market lack any published in vivo testing, even in animal
models, and very little information is available in international
medical databases.
THEY ARE NOT EASILY DETECTABLE IN URINE AND BLOOD SAMPLES
Most of the synthetic cannabinoids added as not-listed ingredients
to Spice products are very difﬁcult to detect by commonly used
drug screening procedures. Apart from the analogs of THC such as
HU-210, the structure of these new synthetic cannabinoids differs
from that of THC, so that they probably will not trigger a positive
test for cannabinoids in immunoassays of body ﬂuids. This has
important consequences, because it encourages not only cannabis
users but also curious people with no previous experience of illicit
drugs to use these products to attain cannabis-like effects, without
having to fear prosecution. Furthermore, wherever drug screening
is routinely performed to guarantee abstinence from drugs (i.e.,
hospital or institutions carrying out detoxiﬁcation, forensic psy-
chiatric centers), people can be motivated to substitute cannabis
with Spice products. Maximal research effort is currently focusing
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on the development of new analytical procedure for measur-
ing urinary concentrations of synthetic cannabinoids and several
potential metabolites of each (Beuck et al., 2011; Grigoryev et al.,
2011; Hudson and Ramsey, 2011; Moran et al., 2011).
WHAT DO THEY CONTAIN?
It is not easy to determine exactly what is in Spice products, due to
the lack of reference samples and the presence of masking agents
of natural origin such as tocopherol (vitamin E), eugenol, or fatty
acids (Dresen et al., 2010), which are commonly added to con-
fuse identiﬁcation. Spice is supposed to contain up to 15 different
vegetal compounds,which gives rise to awide variety of drug com-
binations (Zuba et al., 2011), among which are the psychoactive
herbs known as“WildDagga”(Leonotis leonurus) and“Indianwar-
rior” (Pedicularis densiﬂora). Potentially psychoactive alkaloids,
such as betonicine, aporphine, leonurine nuciferine, or nicotine,
are often declared as ingredients in these products; yet, only some
herbal mixtures have the constituents stated, and most samples
of Spice contain inert vegetable matter. The synthetic psychoac-
tive compounds added to Spice were initially almost unknown
substances, which forensic laboratories had difﬁculties in recog-
nizing and ﬁnding reference samples. A decisive improvement in
the identiﬁcation of these chemicals is the recent development
of a GC–MS screening procedure that combines high chromato-
graphic resolution with the existence of well-established libraries,
offering huge collections of spectra that can be adapted by adding
spectra of emerging psychoactive compounds that have probably
been added to herbal mixtures (Auwärter et al., 2009; Dresen et al.,
2010, 2011).
The active compounds present in Spice products are placed
principally at the surface of the herbal ingredients, and the extrac-
tion procedure is able to remove them without signiﬁcant conta-
mination by the vegetable components of the herb. Unfortunately,
trafﬁcking and detection of these drugs is hampered by the fact
that the exact content of many Spice products still remains unpre-
dictable, because it changes constantly over time as a reaction
to prevention and legal actions, leading to an ever-expanding
array of synthetic cannabinoids being available on the market.
It is clear that comprehension of the clinical pharmacology of
these compounds is essential for practitioners and scientists to
discriminate the relative toxicity associated with the different syn-
thetic cannabinoid mixtures and routes of administration. The
major psychoactive ingredients of Spice products are illustrated in
Figure 2.
CANNABINOIDS
Unlike cannabis, Spice products do not contain the phyto-
cannabinoids cannabidiol (rarely THC) but synthetic cannabi-
noid drugs, which originate from four chemically distinct groups:
(i) the JWH compounds, synthesized by John W. Huffman
(JWH) in the 1980s, of which JWH-018 is the most stud-
ied and best characterized to date; (ii) the CP-compounds, a
cyclohexylphenol series synthesized by Pﬁzer in the 1970s, with
the identiﬁed CP-47,497 and its modiﬁed version CP-47,497-
C8 (obtained by extending the dimethylheptyl side chain to
dimethyloctyl); (iii) the HU-compounds, synthesized in the 1960s
at the Hebrew University; and (iv) the benzoylindoles, such as
FIGURE 2 | Structures of most common psychoactive ingredients of
Spice products: synthetic cannabinoids (JWH-018, JWH-250, CP-47,497,
HU-210), μ-opioid agonists (O-Desmethyltramadol), and fatty acid
derivatives with cannabinoid-like activity (Oleamide).
AM-694 and RCS-4 (Huffman et al., 2008; EMCDDA, 2009;
Lindigkeit et al., 2009; Uchiyama et al., 2009b, 2010, 2011a,b;
United States Drug Enforcement Administration, 2009; Hudson
et al., 2010; Nakajima et al., 2011). The show binding afﬁni-
ties for the CB1 and/or the CB2 receptors (see EMCDDA, 2009
for a comprehensive review), are lipid soluble and non-polar,
and consist of 22 to 26 carbon atoms, which explains why they
volatilize readily when smoked. Contrary to nabilone, a syn-
thetic analog of tetrahydrocannabinol approved by the US Food
and Drug Administration (FDA) to treat chemotherapy-induced
nausea and vomiting, no therapeutic effects have been docu-
mented so far for synthetic cannabinoids detected in these herbal
mixtures.
The family of the JWH compounds is the most numerous
and, although their chemical structures differ greatly from those
of THC, they have a higher afﬁnity to CB1 and/or CB2 recep-
tors and are more potent than THC (Huffman et al., 2003;
Huffman, 2009). Conversely, JWH-015 [(2-methyl-1-propyl-1H-
indol-3-yl)-1-naphthalenylmethanone] acts as a selective CB2
receptor agonist (Aung et al., 2000). At the end of 2008, the
synthetic cannabinoid naphthoylindole, JWH-018, and the cyclo-
hexylphenol CP-47,497, along with one of its active homologs,
CP-47,497-C8, were detected using nuclear magnetic resonance
spectroscopy (Auwärter et al., 2009). JWH-018 (naphthalen-1-yl-
(1-pentylindol-3-yl)methanone) was ﬁrst synthesized during an
analysis aiming at developing new cannabimimetic indole com-
pounds with potential therapeutic effects comparable with those
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of THC (Chin et al., 1999). It belongs to the aminoalkylindole
family and has been shown to have a binding afﬁnity for the
CB1 receptors in the low nanomolar range (∼9 nM; Aung et al.,
2000; Atwood et al., 2010). In cannabinoid receptor expressing
CHO cells, JWH-018 inhibits forskolin-stimulated cAMP produc-
tion (Chin et al., 1999), whereas in HEK293 cells stably expressing
this receptor, it was recently found to activate multiple cannabi-
noid receptor signaling pathways, including the phosphorylation
of ERK1/2 mitogen activated protein kinase and the internaliza-
tion of CB1 receptors (Atwood et al., 2010). Speciﬁcally, JWH-018
dose-dependently inhibits glutamate release in autaptic excita-
tory hippocampal neurons, probably acting on the CB1 receptor,
an effect reversed by administration of the CB1 receptor antag-
onist rimonabant (Atwood et al., 2010). In vivo studies show-
ing that JWH-018 induces analgesia, catalepsy, hypomotility, and
hypothermia, namely the tetrad of behaviors classically caused
by cannabinoids administration (Wiley et al., 1998), have con-
ﬁrmed that this compound acts as a potent and effective CB1
receptor agonist. Speciﬁcally, JWH-018 displayed fourfold afﬁn-
ity to the CB1 receptor and about 10-fold afﬁnity to the CB2
receptor compared with THC (Aung et al., 2000; Huffman et al.,
2005). It is worth nothing that unlike metabolites of most syn-
thetic cannabinoids, JWH-018 hydroxylated metabolites retain
in vitro and in vivo activity at CB1 receptors (Brents et al.,
2011), a ﬁnding that in conjunction with the higher CB1 recep-
tor afﬁnity and activity relative to THC may contribute to the
greater prevalence of adverse effects observed with JWH-018-
containing products relative to marijuana. Other JWH com-
pounds have been identiﬁed in herbal mixtures, such as JWH-
250, which shows high afﬁnity for the CB1 and CB2 receptors
(Dresen et al., 2010, 2011), and the butyl homolog of JWH-
018, JWH-073 (naphthalen-1-yl-(1-butylindol-3-yl)methanone),
which seems to bind more speciﬁcally to the CB1 receptor (Wiley
et al., 1998; Aung et al., 2000). The latter has been recently shown
to act similarly to JWH-018, although it is less potent in inhibit-
ing neurotransmission and slower in producing internalization
of cannabinoid receptors (Atwood et al., 2011). Several studies
have reported a recent decrease in the content of JWH-018 in
Spice products, replaced by JWH-073 (Lindigkeit et al., 2009) or
other synthetic psychoactive cannabinoids (Hudson et al., 2010;
Uchiyama et al., 2010, 2011a), of which JWH-398 is the most
recently identiﬁed in the UK and Germany (Vardakou et al.,
2010). JWH-398 was found to be a very potent non-selective
CB1/CB2 receptor agonist (Huffman, 2009), while in a recent
study, the N -alkyl-3-(1-naphthoyl)indole JWH-122, a very potent
CB1 receptor agonist with a structure closely related to JWH-
018 and JWH-073, has been identiﬁed as a new ingredient of
commercial samples of a Spice product called “Lava Red” (Ernst
et al., 2011).
TheCP-47,497 cannabinoid compound (2-(1R,3S)-3-hydroxy-
cyclohexyl]-5-(2-methyloctan-2-yl)phenol) lacks the classical
cannabinoid chemical structure (tricyclic benzopyran system) and
is 3–28 times more potent than THC (Weissman et al., 1982).
Like its homolog cannabicyclohexanol (CP-47,497-C8), it shows
higher afﬁnity to the receptor CB1 compared to CB2 (Auwärter
et al., 2009), and has THC-like activity in animals (Weissman et al.,
1982; Compton et al., 1992). The concentration–response curve
of CP-47,497-C8 in inhibiting neurotransmission in autaptic hip-
pocampal neuron cultures is nearly identical to that described for
JWH-018 (Atwood et al., 2010, 2011).
The classical cannabinoid HU-210 [(6aR,10aR)-9-(hydroxy-
methyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetra-
hydrobenzo[c] chromen-1-ol)], whose agonistic activity on the
CB1 receptor has been long recognized, is an ingredient of herbal
mixtures in the UK and USA European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA, 2009), where it has been
placed under control since 2009 and 2010, respectively. This syn-
thetic analog of THC was shown to be a full non-selective agonist
at the CB1 and CB2 receptors, and to possess intrinsic afﬁnities for
cannabinoid receptors that exceed those of the high-efﬁcacy ago-
nists, CP 55,940 andWIN 55,212-2 (Howlett et al., 2002). Notably,
the pharmacological effects of HU-210 in vivo are also excep-
tionally long lasting, and in animal models it has been shown
to negatively affect learning (Ferrari et al., 1999) and memory
(Robinson et al., 2007; Mackowiak et al., 2009) processes as well as
sexual behavior (Ferrari et al., 2000).
Among the benzoylindoles, AM-694 [(1-(5-ﬂuoropentyl)-3-
(2-iodobenzoyl)indole)] binds strongly to CB1 andCB2 receptors,
and now represents an example of the latest synthetic cannabinoid
agonists added to Spice that is currently available on the UK mar-
ket, but still not controlled by current UK legislation (Dargan
et al., 2011). Another hazardous benzoylindole is RCS-4 [(4-
methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone)], which is
a synthetic JWH-018 cannabinoid analog with uncertain biolog-
ical activity that, under the name of “Devil Smoke,” is currently
used in combination with JWH-073 (Drugs-Forum, 2011). On
March 11, 2011, it was banned as euphoriant substance by the
Danish Ministry of Health (2011).
It seems reasonable to hypothesize that additional compounds
beside the above-mentioned might also contribute to the behav-
ioral and subjective effects produced by smoking Spice, and that
their different pharmacology might explain the different psy-
choactive effects experienced after smoking Spice. Although the
marijuana-like effects of smoked Spice products are probably due
to activation of CB1 receptor, the potential role of CB2 receptors
in such effects is still to be investigated. Regrettably, cannabinoids
identiﬁed so far in Spice products are believed to be only the tip of
an iceberg; the ﬁrst of a larger number of synthesized substances
with cannabis-like effects mediated by their agonist activity at the
CB1 (and/or CB2) receptor. Currently,more than 100 compounds
with cannabimimetic activities are waiting for identiﬁcation.
OPIOIDS
Besides cannabinoids, other psychoactive substances can be part of
Spice products, such as the synthetic opioidO-desmethyltramadol
(Dresen et al., 2010). This opioid is an active metabolite of the
opioid tramadol, a centrally acting analgesic drug with suspected
abuse liability (Raffa, 2008). Very recently, O-desmethyltramadol
was found as an ingredient of a Spice-like blend called “Krypton,”
in combinationwithKratom(Mitragyna speciosa), anAsiaticmed-
icinal plant that has been used as an herbal drug for a long time
(Arndt et al., 2011; Philipp et al., 2011). Mitragynine, an alka-
loid present in Kratom, acts as a μ-opioid receptor agonist, and
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when combined with O-desmethyltramadol, another potent μ-
opioid agonist, can lead to fatal consequences. Indeed, in less than
1 year, consumption of Krypton had fatal results and caused the
unintentional deaths of nine persons (Kronstrand et al., 2011).
OTHER SUBSTANCES
Oleamide (cis-9,10-octadecenoamide), a fatty acid derivative with
cannabinoid-like activity (Leggett et al., 2004) and hypnotic prop-
erties (Fedorova et al., 2001) is one of the most frequent non-
cannabinoid ingredients associated with Spice products (Dresen
et al., 2010). In association with JWH-018, oleamide is present
in an herbal mixture sold as “Aroma” (Every-Palmer, 2011). In
particular, it was found that “Aroma” contained the highest con-
centration of oleamide and the second highest concentration of
JWH-018 (Uchiyama et al., 2010). Harmine and harmaline, two
reversible inhibitors of themonoamine oxidase enzymewith stim-
ulating central effects (Fortunato et al., 2009, 2010), have also
been found in one of these products in combination with myris-
ticin and asarone (Dresen et al., 2010, 2011). Benzophenone (HM
40) is another undeclared substance found in an herbal mixture,
although most likely it was not added purposely but rather should
be considered a contamination from synthesis (Dresen et al., 2010,
2011).
Many other ingredients are listed on the Spice packets, with
their combinations greatly varying in number and concentration,
often depending on the country of distribution. For example, in
a packet of Spice called “Banana Cream Nuke” bought in an USA
smoke shop, the following ingredients were listed: alfalfa, blue
violet, nettle leaf, comfrey leaf, Gymnema sylvestre, passion ﬂower
leaf, horehound, and neem leaf (Schneir et al., 2011). Notably, this
product caused acute intoxication in two young girls, probably
due to the co-presence of THC, JWH-018, and JWH-073 iden-
tiﬁed among 15 other synthetic cannabinoids, whereas none of
the listed ingredients were detectable (Schneir et al., 2011), with
the only exception of passion ﬂower (Passiﬂora sp.) that is well
known to possess anxiolytic properties (Dhawan et al., 2004). Con-
versely, some packets of Spice sold in the UK declare beach bean
(Canavalia maritima or Canavalia rosea), blue lotus (Nelumbo
nucifera), and dwarf skullcap (Scutellaria nana) as ingredients of
the mixture, for which no safety data are available (Burley, 2008).
Moreover, in Germany, in the past 2 years, head shops were selling
different varieties of herbal mixtures by combining the above-
mentioned plants with white or blue water lily (Nymphaea alba
or Nymphaea caerulea), Indian Warrior (Pedicularis densiﬂora),
Lion’s Ear (also known as Lion’s Tail or Wild Dagga; L. leonurus),
Maconha Brava (Zornia latifolia), and Honeyweed or Siberian
Motherwort (Leonurus sibiricus; Teske et al., 2010). Other plants
commonly used in Spice products in combination with synthetic
cannabinoids includedMarshmallow (Althaea ofﬁcinalis) andDog
Rose or Rosehip (Rosa canina; Seely et al., 2011). Not surprisingly,
no natural cannabinoids were declared as constituents.
WHAT ARE THEIR MAIN EFFECTS?
In a growing number of Internet blogs, Spice is described by users
as able to exert strong cannabis-like effects, but inter- and intra-
batch variations, both in terms of substances present and their
quantity, have also resulted in accidental overdosing that requires
hospitalization (Auwärter et al., 2009). Worryingly, very little is
known about its pharmacology and toxicology in humans, and
virtually nothing has been investigated thus far about the health
implications of its use, either in humans or animals, which ham-
pers appropriate medical treatment of Spice-induced side effects.
The carcinogenic potential caused by inhaling smoke contain-
ing these substances has also not been evaluated (EMCDDA,
2009). Only limited data on the pharmacological properties of
CP-47,497 in animal models and on the metabolism of JWH-
015 in rat liver microsomes are available (Compton et al., 1992;
Zhang et al., 2006). It is noteworthy that CP-47,497 generalized
with THC in drug discrimination studies in rats, that is, it pro-
duces subjective effects similar to those of THC, with an absolute
threshold dose 3–14 times lower than that of THC (Weissman
et al., 1982). Very recently, JWH-018 and CP-47,497 were found
to signiﬁcantly decrease the locomotor activity and increase the
electroencephalogram power spectra in rats (Uchiyama et al.,
2011b).
In general, the desired effects of Spice include a sense of empa-
thy and well-being. However, there is an increasing number of
clinical reports describing patients presenting for emergency med-
ical care after smoking Spice products, the most common symp-
toms being nausea, anxiety, agitation/panic attacks, tachycardia,
paranoid ideation, and hallucinations (Piggee, 2009; Banerji et al.,
2010; Bebarta et al., 2010; Vearrier and Osterhoudt, 2010). On
the Internet, it is possible to ﬁnd a quantity of self-reports of users
experiencing anxiety andpsychotic symptomsafter using synthetic
cannabinoids2. Finally, in the literature, there is one published case
report of tolerance and withdrawal phenomena (Zimmermann
et al., 2009), another of drug-induced psychosis (Müller et al.,
2010), and two clinical studies conducted on psychotic patients
(Every-Palmer, 2010, 2011).
CENTRAL EFFECTS AND COGNITIVE DEFICITS
Spice blends are often described as energizing, euphoric, and dis-
inhibiting (Schifano et al., 2009), which are likely among the
most desirable effects pursued by users. However, halting speech
and avoidant eye contact were observed in a young student who
smoked Spice for 3weeks (Benford and Caplan, 2011). Moreover,
after chronic (8months) daily use, Spice can induce serious cogni-
tive impairment (Zimmermann et al., 2009). Loss of consciousness
and confusion have also been described, as well as unresponsive-
ness, seizures, agitation, and irritation (Seely et al., 2011; Simmons
et al., 2011b).
EMOTIONAL ALTERATIONS
Anxiety is one of the main side effects experienced during
acute intoxication, which resolves within 1–2 h after consump-
tion (Schneir et al., 2011). A sense of extreme anxiety and sudden
depression has been reported during withdrawal from chronic
Spice use (Zimmermann et al., 2009). Paranoia and hallucina-
tions have been observed in some patients (Banerji et al., 2010;
Bebarta et al., 2010; Simmons et al., 2011a). Alterations in mood
and perception after Spice have also been described (Auwärter
2http://www.erowid.org/experiences/subs/expJWH018.shtml#Train Wrecks & Trip
Disasters
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et al., 2009), and two studies has associated the use of synthetic
cannabinoids with exacerbation of cannabis-induced psychosis
(Müller et al., 2010; Benford and Caplan, 2011). Interestingly,
unlike cannabis, Spice blends do not contain cannabidiol, a phy-
tocannabinoids known to possess anxiolytic properties, which is
able to reduced anxiety in both animals (Guimarães et al., 1990;
Moreira et al., 2006) and humans (Bergamaschi et al., 2011; Crippa
et al., 2011). More importantly, cannabidiol displays high potency
as an antagonist of CB1 and CB2 receptor agonists (Thomas
et al., 2007; Pertwee, 2008), and is able to revert not only THC-
induced social withdrawal in rats (Malone et al., 2009) but also
THC-induced anxiety in normal volunteers (Zuardi et al., 1982),
suggesting that lack of this cannabinoid in Spice drugs may exac-
erbate the detrimental effects of these herbal mixtures on emotion
and sociability.
DEPENDENCE ANDWITHDRAWAL
To the best of our knowledge, only one case report in Germany
has described thus far a withdrawal syndrome after discontinua-
tion from smoking Spice (Zimmermann et al., 2009). Speciﬁcally,
withdrawal phenomena and a dependence syndrome have been
described after chronic consumption of an herbal mixture called
“Spice Gold” (typically containing CP-47,497-C8 and JWH-018)
in a 20-year-old man, who had a history of smoking this prod-
uct daily for 8months as the only relief from his internal unrest
and nervousness. He found Spice relaxing and sedative, with psy-
choactive effects very similar to those of cannabis. He entered
hospital voluntarily, requesting medical treatment for detoxiﬁca-
tion of Spice after experiencing a similar syndrome a few weeks
earlier during a phase of abstinence owing to a short supply.
Internal unrest and profuse sweating were among the ﬁrst symp-
toms observed by doctors, followed by drug craving, nocturnal
nightmares, tremor, and headache. Other physical withdrawal
symptoms included palpitation, nausea and vomiting, and were
not dissimilar from those described during cannabis withdrawal
(Budney andHughes, 2006). Besides a clear withdrawal syndrome,
a diagnosis of dependency was conﬁrmed by the development
of drug tolerance (the patient had to increase rapidly the dose
from 1 to 3 g/day), persistence of drug craving (he felt a continu-
ous strong desire for the drug), the continuous urge to consume
it despite the adverse consequences (cognitive impairments and
risk of losing his professional training position), and the scarce
attention to other interests or duties (participation in practical
work).
PSYCHOTIC EFFECTS
The link between cannabis use and the occurrence of psychotic
episodes is widely recognized, although it has not been determined
yet whether abuse of the drug in psychotic patients antedates
the onset of the pathology or it is a consequence of the disorder
(Arseneault et al., 2002). Indeed, regular cannabis use is thought
to increase the risk of developing psychosis and to facilitate the
manifestation of the disorder in vulnerable individuals. On the
other hand, patients smoke cannabis to self-medicate the nega-
tive symptoms of schizophrenia or the side effects of antipsychotic
medications. The great medical interest in examining the effects
of these synthetic cannabinoids on the psychotic population is
therefore not surprising. Few data are available on the psychologi-
cal and other risks of synthetic cannabinoids; nevertheless, despite
the limited number of clinical observations, in the Internet fora,
a growing number of users have reported experiencing psychotic
symptoms after smoking Spice.
A ﬁrst case report described the effects of Spice on a 25-year-old
man who had a history of cannabis-induced recurrent psychotic
episodes (Müller et al., 2010). It was found that Spice triggered
not only acute exacerbation of cannabis-induced recurrent psy-
chotic episodes, but also the manifestation of new symptoms,
such as recurrent paranoid hallucinations (Müller et al., 2010).
To such an acute reactivation of symptoms after abuse of Spice
could have contributed the absence of cannabidiol, which is pre-
sumed to have antipsychotic potency (Zuardi et al., 2006; Zullino
et al., 2007), thus suggesting a higher potency for psychosis of
these substances. In line with this, relapses following the use of a
Spice product in psychotic patients have been reported by foren-
sic services (Every-Palmer, 2010). More recently, psychotic relapse
after smoking Spice was conﬁrmed in 15 psychotic New Zealand
patients, all familiar with a locally available JWH-018-containing
product called “Aroma” (Every-Palmer, 2011). Intriguingly, no
one of these patients reported withdrawal symptoms or physi-
cal distress after using the Spice product, three of them described
developing some tolerance to the product, and 13 acknowledged
having smoked “Aroma” as a cannabis substitute. A latest study
described the case of a young student experiencing severe anx-
iety, paranoia, and both visual and auditory hallucinations after
repeated (3weeks) use of Spice (Benford and Caplan, 2011). Thus,
evidence seems to indicate that Spice products can precipitate psy-
chosis in vulnerable individuals, implying the necessity of advis-
ing people with risk factors for psychosis against using synthetic
cannabinoids.
PERIPHERAL EFFECTS
Although gastrointestinal effects, such as nausea, vomiting, and
retching, are the most common after consumption of Spice, car-
diovascular effects, such as extremely elevated heart rate and blood
pressure, chest pain, and cardiac ischemia are among the most
dangerous consequences (Canning et al., 2010; Schneir et al., 2011;
Seely et al., 2011). Occasional inappropriate laughter, injected con-
junctiva, xerostomia, and nystagmus have been described as well
(Auwärter et al., 2009; Schneir et al., 2011). Spice also induces
metabolic effects, such as hypokalemia, hyperglycemia, and acido-
sis, and autonomic effects, such as fever and mydriasis (Seely et al.,
2011; Simmons et al., 2011a).
LETHAL EFFECTS
Contrary to the partial action of THC at the CB1 receptor, syn-
thetic cannabinoids identiﬁed so far in Spice products have been
shown to act as full agonists with increased potency, thus leading to
longer durations of action and an increased likelihood of adverse
effects. Although limited at the moment, some life-threatening
symptoms have been reported by subjects that use these prod-
ucts as marijuana substitutes, and coma and suicide attempts
have been reported after smoking the dangerous spice drug K2
(Missouri Department of Health and Senior Services, 2010). Dra-
matically, two adolescents died in the USA after ingestion of a
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Spice product called “K2,” one due to a coronary ischemic event
(Fisher, 2010), and the other committed suicide due to the unbear-
able sense of extreme anxiety (Gay, 2010). The non-cannabinoid
ingredient of many Spice products, namely the opioid agonist O-
desmethyltramadol, when used in combination with Kratom (as
in the mixture known as Krypton), may have lethal consequences
(Kronstrand et al., 2011).
CONCLUDING REMARKS
Spice drugs include a large range of products sold as “ethno drugs”
or legal substitutes for cannabis since 2004. From the end of 2008,
some potent synthetic cannabinoids, such as JWH-018 and CP-
47,497, were identiﬁed as psychoactive ingredients of these herbal
blends, and some countries placed them under control. Due to
their powerful psychoactivity, ready availability on the Internet,
legal status, and non-detection in drug testing, Spice products have
acquired anunexpectedpopularity, especially amongyoungest and
ﬁrst-time consumers, including college students (Hu et al., 2011).
Synthetic cannabinoids currently available on the market have
been shown to induce severe peripheral and central effects, includ-
ing drug dependence and psychosis. Yet, these products provide
very limited safety information about their effects and possi-
ble health consequences, so that uninformed users risk serious
adverse effects. This renders it very complicated, if not impossi-
ble, for health professionals and clinicians to carry out accurate
assessments of possible drug-related medical and psychiatric con-
sequences of their use. The emergence of the Internet as the major
player in shaping the international Spice market has led to sig-
niﬁcant public health concerns. Continuous monitoring of herbal
mixtures available online is essential for timely detection of new
chemicals, which will continue to be developed as a reaction to
the newly implemented control measures (Uchiyama et al., 2009b,
2010, 2011a; Dresen et al., 2010, 2011; Dowling and Regan, 2011;
Westphal et al., 2011).
FUTURE PERSPECTIVES
Very limited information is available on the safety of the Spice
ingredients in humans, and the occurrence of serious health dam-
age in their abusers is highly probable. Rapid detection and identi-
ﬁcation of new synthetic cannabinoids in human urine and blood
samples would greatly restrict their use and diffusion. Up to the
beginning of 2010, the ﬁrst methodologies for the quantiﬁcation
of synthetic cannabinoids in human serum have been developed
and validated in accordancewith conventional screening protocols
based on enzymatic hydrolysis, liquid–liquid extraction, and liquid
chromatography/electrospray tandem mass spectrometry analysis
(Müller et al., 2010; Teske et al., 2010). Researchers should con-
tinue to develop rapid and reliable detection screening procedures,
because they would be crucial formedical staff in assisting patients
at the emergency units, to psychiatrists in recognizing and treat-
ing psychiatric symptoms, and to police authorities in assessing
ﬁtness to drive. Evidence that the synthetic cannabinoids are not
detectable in human body ﬂuids underlines the need to elucidate
their metabolic pathways and identify their metabolites, which
could shed light on their pharmacokinetics and toxicity (Winter-
meyer et al., 2010). Cannabinoids have been classiﬁed as doping
substances by theWorldAnti-DopingAgency (WADA,2011), thus,
screening for the synthetic cannabinoids and their major metabo-
lites could also be applied to human urine doping controls (Müller
et al., 2010).
In countries where synthetic cannabinoids are under control,
incessant monitoring of the manufacture, distribution, and use
of marketed Spice-like products is necessary. Given the world-
wide spread of these herbal mixtures, an international coop-
eration system is mandatory for sharing analytical information
and improving monitoring of the global drug market. In coun-
tries where synthetic cannabinoids are marketed legally, accurate
labeling of products containing psychoactive compounds should
be requested, so that users can be conscious of the potential
risks associated. In both cases, however, it will be an ongo-
ing challenge to detect synthetic cannabinoids in herbal mix-
tures and to include them in analytical methods. Future research
should focus on the study of their pharmacological effects, both
at the central (dependence, psychosis, anxiety, depression) and
peripheral (tremor, nausea, tachycardia, headache) levels, as well
as on the evaluation of the health consequences of smoking
Spice repeatedly. This is also to avoid the risk of banning com-
pounds with not health hazarding proﬁle which would probably
be replaced quickly by more dangerous substances (Hammers-
ley, 2010). More importantly, understanding of the neurobio-
logical bases of such compounds activity might encourage the
development of synthetic cannabinoids that produce therapeu-
tic effects with a minimum of psychoactive effects, such as the
synthetic THC dronabinol (Marinol), the synthetic THC ana-
log nabilone (Cesamet), and the standardized cannabis extract
(Sativex).
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